Arvinas (NASDAQ:ARVN) initiates its second clinical program with the launch of a Phase 1 study assessing ARV-471 in patients with locally advanced/metastatic ER+/HER2- breast cancer. Preliminary data should be available in 2020.
The primary objective is safety, tolerability and pharmacokinetics. Secondary endpoints include pharmacodynamics and anti-tumor activity.
ARV-471 is an oral estrogen receptor-targeting PROTAC protein degrader. PROTAC (Proteolysis-Targeting Chimera) molecules degrade disease-causing proteins via the cell’s natural protein degrading process called the ubiquitin/proteasome system.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.